Literature DB >> 9512954

Antibiotic use, childhood affluence and irritable bowel syndrome (IBS).

M A Mendall1, D Kumar.   

Abstract

BACKGROUND: Antibiotics cause well defined short-lived disturbances in bowel habit. There is evidence to suggest that antibiotics may play a role in the pathogenesis of IBS. Atopy has been associated with small household size in childhood and could also play a role in IBS. We conducted a survey examining the relation of drug use and other epidemiological correlates of IBS.
SETTING: General practice health screening clinic. SUBJECTS AND METHODS: 421 subjects (46% male, mean age 47 years (range 18-80 years) attending a general practice health screening clinic were interviewed by a research nurse and completed a previously validated questionnaire. Symptoms of IBS were said to be present if abdominal pain with 2 or more Manning criteria symptoms occurred more than once per month over the previous 6 months.
RESULTS: 48 subjects had symptoms of IBS. The following were strongly related to its presence: antibiotic use [adjusted OR 3.70 (1.80-7.60)], female sex and childhood living density < 1 person per room [OR 3.47 (1.57-7.64)], manual father's occupation [OR 0.35 (0.16-0.76)]. The use of NSAIDS, H2 antagonists or other types of medication was not greater in this group.
CONCLUSION: Antibiotic use is associated with IBS. The association with antibiotic use requires testing in prospective studies. Privileged childhood living conditions were also an important risk factor which is consistent with an allergic aetiology for IBS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512954     DOI: 10.1097/00042737-199801000-00011

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  31 in total

1.  Infections, medication use, and the prevalence of symptoms of asthma, rhinitis, and eczema in childhood.

Authors:  Catherine Cohet; Soo Cheng; Claire MacDonald; Michael Baker; Sunia Foliaki; Nyk Huntington; Jeroen Douwes; Neil Pearce
Journal:  J Epidemiol Community Health       Date:  2004-10       Impact factor: 3.710

2.  Do probiotics improve symptoms in patients with irritable bowel syndrome?

Authors:  Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 3.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

4.  Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study.

Authors:  M A McNally; G R Locke; A R Zinsmeister; C D Schleck; J Peterson; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2008-08-01       Impact factor: 8.171

5.  Deployment-associated functional gastrointestinal disorders: do we know the etiology?

Authors:  Ashok K Tuteja
Journal:  Dig Dis Sci       Date:  2011-11       Impact factor: 3.199

6.  Irritable bowel syndrome: bacteria and inflammation--clinical relevance now.

Authors:  Robin C Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 7.  Intestinal microbiota and its role in irritable bowel syndrome (IBS).

Authors:  Lena Ohman; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2013-05

8.  Prevalence of gastrointestinal diseases in two British national birth cohorts.

Authors:  A G C Ehlin; S M Montgomery; A Ekbom; R E Pounder; A J Wakefield
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 9.  Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease.

Authors:  Joseph M Pickard; Melody Y Zeng; Roberta Caruso; Gabriel Núñez
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

Review 10.  Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend?

Authors:  G Reid; K Anukam; T Koyama
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.